A Case of Refractory SAPHO Syndrome Treated with Etanercept.
- Author:
Ye Ji KIM
1
;
Song I BAE
;
Sung Jae CHOI
;
Young Ho LEE
;
Jong Dae JI
;
Gwan Gyu SONG
Author Information
- Publication Type:Case Report
- Keywords: SAPHO syndrome; Treatment; TNF-alpha blocker
- MeSH: Acne Vulgaris; Acquired Hyperostosis Syndrome; Adrenal Cortex Hormones; Antirheumatic Agents; Diphosphonates; Hyperostosis; Immunoglobulin G; Inflammation; Osteitis; Receptors, Tumor Necrosis Factor; Skin; Synovitis; Tumor Necrosis Factor-alpha; Etanercept
- From:Journal of Rheumatic Diseases 2012;19(1):51-54
- CountryRepublic of Korea
- Language:Korean
- Abstract: SAPHO syndrome, which has different skin changes and osteoarticular inflammation, is an acronym that stands for synovitis, acne, pustulosis, hyperostosis, and osteitis. Treatment of SAPHO syndrome includes non-steroidal anti-inflammatory drugs (NSAIDs), anti-rheumatic drugs, such as colchicines, corticosteroids and bisphosphonates, and disease-modifying agents. However, the treatment of SAPHO syndrome is controversial because it is a new clinical entity with unclear etiopathogenesis and inadequate clinical studies. We report a case with refractory SAPHO syndrome, which was successfully treated with a tumor necrosis factor (TNF)-alpha blocker.
